Classification of anticancer drugs - A new system based on therapeutic targets

Cancer Treatment Reviews

Volumn 29, Issue 6, 2003, Pages 515-523

  Espinosa, Enrique ^a   Zamora, Pilar ^a   Feliu, Jaime ^a   González Barón, Manuel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antineoplastic drugs; Chemotherapy; Classification; Monoclonal antibodies; New drugs; Small molecules

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CANERTINIB; CISPLATIN; DNA; DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLAVOPIRIDOL; GEFITINIB; IDARUBICIN; IMATINIB; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; RNA; SEMAXANIB; TIPIFARNIB; TIRAPAZAMINE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG DNA INTERACTION; DRUG TARGETING; ENDOTHELIUM; EXTRACELLULAR MATRIX; GENE TARGETING; HEAD AND NECK TUMOR; HOST CELL; HUMAN; IMMUNE SYSTEM; LUNG NON SMALL CELL CANCER; REVIEW; TUMOR CELL;

EID: 0242475357     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00116-6     Document Type: Article

References (93)

1. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002; 2(3): 188-200.
2. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002; 128(11): 603-609.
3. Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002; 29(4 Suppl 13): 19-22.
4. Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13(8): 1285-1289.
5. Gandara DR, Lara Jr PN, Goldberg Z, Le QT, Mack PC, Lau DH, et al. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 2002; 29(1 Suppl 4): 102-109.
6. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 2002; 62(18): 5248-5253.
7. Giovanella BC, Stehlin JS, Hinz HR, Kozielski AJ, Harris NJ, Vardeman DM. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). Int J Oncol 2002; 20(1): 81-88.
8. Schoffski P, Herr A, Vermorken JB, Van den Brande J, Beijnen JH, Rosing H, et al. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 2002; 38(6): 807-813.
9. Emerson DL, Bendele R, Brown E, Chiang S, Desjardins JP, Dihel LC, et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 2000; 6(7): 2903-2912.
10. Kehrer DF, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol 2002; 20(5): 1222-1231.
11. Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, et al. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 2002; 8(7): 2134-2141.
12. Minami H, Fujii H, Igarashi T, Itoh K, Tamanoi K, Oguma T, et al. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 min every three weeks. Clin Cancer Res 2001; 7(10): 3056-3064.
13. Calvert H, Bunn Jr PA. Future directions in the development of pemetrexed. Semin Oncol 2002; 29(2 Suppl 5): 54-61.
14. Novello S, le Chevalier T. ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer. Lung Cancer 2001; 34(Suppl 4): S107-S109.
15. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001; 85(5): 649-655.
16. Scotto KW. ET-743: more than an innovative mechanism of action. Anticancer Drugs 2002; 13(Suppl 1): S3-S6.
17. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity. J Clin Oncol 2001; 19(5): 1248-1255.
18. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6(1): 34-55.
19. Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001; 28(4 Suppl 15): 67-70.
20. Del Bufalo D, Cucco C, Leonetti C, Citro G, D'Agnano I, Benassi M, et al. Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br J Cancer 1996; 74(3): 387-393.
21. Strasberg Rieber M, Zangemeister-Wittke U, Rieber M. p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Clin Cancer Res 2001; 7(5): 1446-1451.
22. Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med 2002; 8(4): 185-199.
23. Rait AS, Pirollo KF, Rait V, Krygier JE, Xiang L, Chang EH. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther 2001; 8(10): 728-739.
24. Funato T, Kozawa K, Fujimaki S, Miura T, Kaku M. Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. Chemotherapy 2001; 47(4): 297-303.
25. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002; 13(11): 1699-1716.
26. Henry SP, Geary RS, Yu R, Levin AA. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Investig Drugs 2001; 2(10): 1444-1449.
27. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol 2002; 3(11): 672-683.
28. Sandberg JA, Parker VP, Blanchard KS, Sweedler D, Powell JA, Kachensky A, et al. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J Clin Pharmacol 2000; 40(12 Pt 2): 1462-1469.
29. Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001; 3(2): 141-146.
30. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18(17): 3135-3143.
31. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18(6): 1316-1323.
32. Iodine-131 tositumomab (Bexxar) in relapsed/refractory non-Hodgkin's lymphoma: Update from the 2001 American Society of Hematology Meeting. Clin Lymphoma 2002; 2(4): 209-211.
33. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20(18): 3891-3897.
34. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100(3): 768-773.
35. Roboz GJ, Knovich MA, Bayer RL, Schuster MW, Seiter K, Powell BL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leukemia Lymphoma 2002; 43(10): 1951-1955.
36. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16(9): 1627-1636.
37. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002; 29(3 Suppl 11): 38-43.
38. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62(1): 209-243.
39. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001; 37(Suppl 4): S16-S22.
40. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19(13): 3234-3243.
41. Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998; 76(6): 817-823.
42. Herbst RS, Kies MS. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist 2002; 7(Suppl 4): 9-15.
43. Ranson M. ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist 2002; 7(Suppl 4): 16-24.
44. Hidalgo M, Sin LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19(13): 3267-3279.
45. Baker CH, Kedar D, McCarty MF, Tsan R, Weber KL, Bucana CD, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002; 161(3): 929-938.
46. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002; 29(3 Suppl 11): 11-21.
47. Cohen MH, Moses ML, Pazdur R. Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Oncologist 2002; 7(5): 390-392.
48. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3(11): 655-664.
49. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming ST1571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100(3): 1068-1071.
50. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol 2001; 13(6): 470-476.
51. Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002; 8(25): 2249-2253.
52. Dancey JE. Agents targeting ras signaling pathway. Curr Pharm Des 2002; 8(25): 2259-2267.
53. Elit L. CCI-779 Wyeth. Curr Opin Investig Drugs 2002; 3(8): 1249-1253.
54. Brockstein B, Samuels B, Humerickhouse R, Arietta R, Fishkin P, Wade J, et al. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs 2001; 19(3): 249-254.
55. Pfister DG, McCaffrey J, Zahalsky AJ, Schwartz GK, Lis E, Gerald W, et al. A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Invest New Drugs 2002; 20(1): 123-127.
56. Virchis A, Ganeshaguru K, Hart S, Jones D, Fletcher L, Wright F, et al. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol J 2002; 3(3): 131-136.
57. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002; 6(4): 493-500.
58. Orlowski R, Stinchcombe E, Mitchell B, Shea T, Baldwin A, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20(22): 4420-4427.
59. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999; 17(4): 361-373.
60. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61(5): 1799-1804.
61. Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002; 20(8): 2157-2170.
62. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002; 102(5): 463-468.
63. Koh J, Kubota T, Migita T, Abe S, Hashimoto M, Hosoda Y, et al. UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction. Breast Cancer 2002; 9(1): 50-54.
64. Senderowicz AM. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002; 7(Suppl 3): 12-19.
65. Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2001; 7(7): 2016-2021.
66. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7(5): 1429-1437.
67. Stachel SJ, Biswas K, Danishefsky SJ. The epothilones, eleutherobins, and related types of molecules. Curr Pharm Des 2001; 7(13): 1277-1290.
68. Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001; 7(9): 2675-2681.
69. Raje N, Anderson KC. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002; 14(6): 635-640.
70. Figg WD, Kruger EA, Price DK, Kim S, Dahut WD. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002; 20(2): 183-194.
71. Waselenko JK, Shinn CA, Willis CR, Flinn IW, Grever MR, Byrd JC. Carboxyamido-triazole (CAI) - a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells. Leukemia Lymphoma 2001; 42(5): 1049-1053.
72. Dreau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL. Angiogenic and immune parameters during recombinant interferon-α2b adjuvant treatment in patients with melanoma. Oncol Res 2000; 12(5): 241-251.
73. Kawano Y, Matsui N, Kamihigashi S, Narahara H, Miyakawa I. Effects of interferon-gamma on secretion of vascular endothelial growth factor by endometrial stromal cells. Am J Reprod Immunol 2000; 43(1): 47-52.
74. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62(3): 625-631.
75. Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 2002; 112(5): 839-843.
76. Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 2002; 3(1): 28-30.
77. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Huntingt) 2001; 15(8): 1017, 1020, 1023-1026.
78. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002; 8(9): 2798-2805.
79. Fabbro D, Manley P. Su-6668. SUGEN. Curr Opin Investig Drugs 2001; 2: 1142-1148.
80. Hoekman K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J 2001; 7(Suppl 3): S134-S138.
81. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62(12): 3408-3416.
82. Ohno T, Kawano K, Sasaki A, Aramaki M, Tahara K, Etoh T, et al. Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int J Clin Oncol 2002; 7(3): 171-176.
83. Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001; 6(5): 415-427.
84. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86(12): 1864-1870.
85. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87(2): 161-167.
86. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002; 20(5): 1383-1388.
87. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002; 13(8): 1259-1263.
88. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001; 28(6): 620-625.
89. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res 2000; 6(8): 3056-3061.
90. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, et al. Pilot study of vitaxin - an angiogenesis inhibitor - in patients with advanced leiomyosarcomas. Cancer 2001; 92(5): 1347-1348.
91. Coleman RE. Treatment of skeletal complications of cancer with zoledronic acid. Semin Oncol 2002; 29(Suppl 21): 1-49.
92. Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 2002; 10: 399-407.
93. Body JJ, Greip P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97(Suppl 3): 887-892.